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Abstract
Background: Without neonatal initiation of treatment, 80–90% of patients with glutaric aciduria type 1 (GA1)
develop striatal injury during the first six years of life resulting in a complex, predominantly dystonic movement
disorder. Onset of motor symptoms may be acute following encephalopathic crisis or insidious without apparent
crisis. Additionally, so-called late-onset GA1 has been described in single patients diagnosed after the age of 6 years.
With the aim of better characterizing and understanding late-onset GA1 we analyzed clinical findings, biochemical
phenotype, and MRI changes of eight late-onset patients and compared these to eight control patients over the
age of 6 years with early diagnosis and start of treatment.
Results: No late-onset or control patient had either dystonia or striatal lesions on MRI. All late-onset (8/8) patients
were high excretors, but only four of eight control patients. Two of eight late-onset patients were diagnosed after
the age of 60 years, presenting with dementia, tremor, and epilepsy, while six were diagnosed before the age of
30 years: Three were asymptomatic mothers identified by following a positive screening result in their newborns
and three had non-specific general symptoms, one with additional mild neurological deficits. Frontotemporal
hypoplasia and white matter changes were present in all eight and subependymal lesions in six late-onset patients.
At comparable age a greater proportion of late-onset patients had (non-specific) clinical symptoms and possibly
subependymal nodules compared to control patients, in particular in comparison to the four clinically and MR-wise
asymptomatic low-excreting control patients.
Conclusions: While clinical findings are non-specific, frontotemporal hypoplasia and subependymal nodules are
characteristic MRI findings of late-onset GA1 and should trigger diagnostic investigation for this rare disease. Apart
from their apparent non-susceptibility for striatal injury despite lack of treatment, patients with late-onset GA1 are
not categorically different from early treated control patients. Differences between late-onset patients and early
treated control patients most likely reflect greater cumulative neurotoxicity in individuals remaining undiagnosed
and untreated for years, even decades as well as the higher long-term risk of high excretors for intracerebral
accumulation of neurotoxic metabolites compared to low excretors.
Keywords: Glutaric aciduria type I, Late-onset, Long-term disease course, Subependymal nodules, Frontotemporal
hypoplasia, High excretor
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Background
In glutaric aciduria type 1 (GA1, OMIM#231670), a rare
inherited metabolic disease, deficiency of glutaryl-CoA
dehydrogenase results in accumulation of the putatively
neurotoxic metabolites glutaric and 3-hydroxyglutaric
acid (GA, 3-OH-GA) in body tissues, particularly within
the brain. Two biochemical phenotypes, low and high
excretors, have been defined based on urinary excretion
of GA [1].
Without treatment the majority of patients develops
an acute encephalopathic crisis during catabolic states,
i.e. febrile illness, possibly triggered by vaccinations, or
surgical procedures, during the first six years of life
(“acute-onset type”), with acute striatal injury and subse-
quent complex movement disorder which may be best
described as dystonia superimposed on axial muscular
hypotonia [2]. In contrast, most patients diagnosed by
newborn screening (NBS) and treated according to
guideline recommendations since neonates, remain
asymptomatic [3]. Two further clinical subtypes have
been proposed: insidious- and late-onset types. Patients
with insidious-onset (about one third of symptomatic pa-
tients [4]) develop a complex dystonic movement dis-
order due to striatal injury but without clinically
apparent precipitating event [2–8].
The term late-onset has been used for patients diag-
nosed after the age of six years, who presented with - in
comparison to patients with acute or insidious onset
types - non-specific and sometimes longstanding symp-
toms and predominantly white matter changes on MRI
[9–13]. Case reports on late-onset GA1 include four
women, whose diagnostic work-up was initiated follow-
ing their unaffected newborns’ positive NBS (maternal
GA1), but not because of neurological presentation. Due
to transplacental exchange, decreased concentrations of
free maternal carnitine or increased maternal glutaryl-
carnitine can be detected by NBS in the non-affected
neonate. Neonatal parameters normalize during the fol-
lowing weeks and confirmatory work-up of the non-
affected neonate is negative which then triggers investi-
gation of the mothers [14–16].
Current literature on late-onset GA1 only consists of
case reports. With the aim of better characterizing and
understanding late-onset GA1 we systematically evalu-
ated clinical findings, biochemical phenotype (high/low
excretor), and MRI changes in a sample of eight late-on-
set patients and compared these to eight control patients
older than 6 years, who had been diagnosed and treated
early.
Methods
As part of our ongoing prospective study on long-term
outcome of GA1 patients in Germany since 2002 [3, 17]
we identified those patients who met diagnostic criteria
of late-onset GA1 based on systematic evaluation of pre-
viously reported individuals with presumptive late-onset
disease, namely (1) diagnosis after the age of 6 years, (2)
absence of dystonic movement disorder, and (3) absence
of striatal lesions on cerebral MRI. These late-onset pa-
tients were compared to control GA1 patients who (1)
had been diagnosed and treated within the first three
years of life, (2) had reached the age of at least 6 years,
and had (3) neither clinical evidence of a dystonic move-
ment disorder (4) nor striatal lesions on cerebral MRI.
Using these criteria we identified eight late-onset pa-
tients with a total of 22 MRI scans (age at diagnosis 8.5-
71 years, age at MRI 8.5-73.8 years), including two pa-
tients previously published by our group [12] and a fur-
ther patient whose initial case was presented in [18].
Eight control patients (age at diagnosis 8 days–
36 months) with a total of 15 MRI scans performed be-
tween the ages of 6.2 and 22.1 years were identified for
comparison. Initial findings of three of these have previ-
ously been reported as cases by us (c1 = case 2
(≤50 months), c2 = case 3 (≤36 months), c6 = case 4
(≤15 years) in [18]).
MRI scans were assessed for (a) frontotemporal hypo-
plasia, presence of abnormal (b) gray and/or (c) white
matter signal [18], and (d) space-occupying lesions by an
experienced paediatric neuroradiologist.
Clinical, biochemical and genetic patient characteris-
tics are summarized in Table 1. Biochemical phenotype
(low/high excretor) was classified based on urinary con-
centrations of GA (in mmol/mol creatinine) at time of
diagnosis. Initial values were not available for the high-
excreting patient 7, however, concentration on follow-up
investigation was clearly elevated > 100 mmol GA/mol
creatinine and thus within the range for high excretors
[1]. It is known that urinary concentrations of GA and
3-OH GA remain elevated in high excretors despite
some reduction with dietary treatment and do not de-
crease to the range of low excretors (<100 mmol/mol
creatinine) [4, 19, 20].
Mutation analysis of the GCDH gene on chromosome
19p13.2 was performed using gDNA sequencing of all
11 exons with contiguous introns and was documented
as changes of protein code (“p.” code) in all patients ex-
cept patient 6, whose four other affected family mem-
bers all carry the same mutation (p.Glu365Lys/
p.Glu365Lys). In this patient as well as in p2, c1, c2, c4,
and c8 measurement of residual enzyme activity in leu-
kocytes had additionally been performed (Table 1).
With the exception of one late-onset patient without
oral carnitine supplementation (p6), all control and late-
onset patients were treated according to guideline rec-
ommendations [21]: All patients over the age of 6 years
followed a protein-controlled diet using natural protein
with a low lysine content and avoiding lysine-rich food
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and orally supplemented carnitine. Until the age of
6 years the early diagnosed control patients received
combined metabolic therapy consisting of a low-lysine
diet, carnitine supplementation, and a high-caloric, low-
or no-protein emergency dietary regimen during epi-
sodes likely to induce catabolism.
Results
Diagnosis and clinical presentation
The eight late-onset patients were diagnosed between
8.5 and 71 years, five by targeted metabolic screening,
two after diagnostic work-up of an initially abnormal
NBS result of their newborns (“maternal GA1”, p3,4),
and one female (p6) by high-risk family screening fol-
lowing diagnosis of her macrocephalic infant. According
to the definition of Baric et al. [1], all eight late-onset pa-
tients were high excretors compared to four of the eight
control patients (Table 1). Pathogenic variations (protein
code changes “p.”) in the GCDH gene detected by mo-
lecular genetic analysis were different in all patients ex-
cept for the siblings (c4/c8, c6/c7; Table 1).
Of the six late-onset patients diagnosed before the
age of 30 years, the three patients identified via their in-
fants (p3, p4, p6) were asymptomatic at diagnosis
whereas the other three had non-specific, general
symptoms like nausea, vertigo, and/or headaches, one
(p2) with additional mild neurological deficits (impaired
fine motor skills and motor balance). The two oldest
patients (p7, p8) diagnosed at the age of 66 and 71 years
presented with severe neurologic symptoms, namely
dementia, tremor, and epilepsy. In p7 this had been
preceded by several stroke-like episodes since the age
of 61 years to which reduced strength of left upper ex-
tremity was attributed. Four patients (p2, p6-8) were
macrocephalic and for two this had been documented
since infancy (p2, p6). For six patients (p1-5, p8) vari-
ous, minor febrile infections during infancy are known.
In addition p4 had toxoplasmosis at age 19 years, p5
had two febrile seizures, and p3 had foot surgery at the
age of 7 years. All patients fully recovered after each
event and none developed symptoms of an acute an en-
cephalopathic crisis or signs of an extrapyramidal
movement disorder.
At last follow-up two of the six patients diagnosed be-
fore the age of 30 were asymptomatic; four had head-
aches, one with intermittent vertigo and one with
coordination deficits and cognitive disability, but no evi-
dence of cerebellar dysfunction. In the two patients diag-
nosed after the age of 60 years, dementia, tremor, and
epilepsy persisted, in p8 with additional dysarthria, inter-
mittent orofacial dyskinesia, dysmetria, and reduced fine
motor skills. In p7 dementia was progressive and fre-
quency of seizures increased despite metabolic and anti-
convulsive treatment, moreover urinary and rectal
incontinence developed (for detailed case report of p7
see Additional file 1).
Of the eight control patients four were diagnosed by
NBS, one however without adequate diagnostic work-up
and final diagnosis by targeted screening for macroceph-
aly at age of two months (c3). The other four patients
were diagnosed before implementation of NBS by high-
risk family screening due to an affected twin or older
sibling (c5, c6) and by targeted screening for global de-
velopmental delay and macrocephaly (c7, c8). Except for
unspecific intermittent vertigo in c8, all control patients
were asymptomatic at last follow-up. Macrocephaly had
resolved in c3 and persisted in two brothers (c6, c7),
while none of the others were macrocephalic. No late-
onset or control patient showed signs of a dystonic
movement disorder at diagnosis or last follow-up visit.
Frontotemporal hypoplasia
All late-onset patients had frontotemporal hypoplasia
(Table 2), which remained unchanged over a period of
seven, eleven and twelve years in the three late-onset pa-
tients with serial MRIs (p1, p4, p7). Frontotemporal hy-
poplasia was mild in four patients (anterior Sylvian
fissure not widened beyond the pars opercularis; p1, p3-
5), moderate in two (involvement of subcentral gyrus;
p2, p6), and most severe in the oldest patients with ap-
parent expansion in p7 (Fig. 1).
Frontotemporal hypoplasia was less frequent in con-
trol patients: Five of eight control patients had no fron-
totemporal hypoplasia. The youngest control patient (c1)
had mild, residual hypoplasia, and the two macroceph-
alic brothers (c6, c7) had continuously wide open Sylvian
fissures, all three of these high-excretors.
White matter changes
All late-onset patients had white matter changes, pre-
dominantly of periventricular and lobar, frontal and par-
ietal white matter. They were extensive in five (p1-4, p8;
asymmetric in p8) and less extensive with additional
multifocal, somewhat asymmetric hyperintensities in
three patients (p5 (Fig. 2b), p6, p7). In the oldest patients
they were indistinguishable from white matter changes
associated with ageing and arterial hypertension and
new lesions in p7 during follow-up could not be dif-
ferentiated from cerebrovascular changes (Fig. 2g,h).
Extent of white matter changes slightly increased over
7 years’ follow-up in p1 (Fig. 2c,d), and was not pro-
gressive in p4.
White matter changes were present in only three of
eight control patients, all of these high excretors: The
youngest (c1, Fig. 2a) had periventricular and the macro-
cephalic brothers had extensive white matter changes
(c6, c7), in the latter not progressive during 8 years’
follow-up (Fig. 2e,f ).
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Table 2 Neuroradiological characteristics of late-onset type and control GA1 patients (listed according to age at MRI)
High/low
excretor
Age at Subependymal lesions min. slice
thickn.
wm
changes
gm changes Fronto-temp.
hypoplasiadiagnosis at MRI y/n n= max diam. [mm]
Pat. #
p1a high 8.5 years 8.5 years n - - 3.5 mm y pall., thal., dent. y
9.5 years n - - 3.5 mm y pall., thal., dent. y
10.4 years n - - 1 mm y pall., thal., dent. y
11.9 years n - - 1 mm y pall., thal., dent. y
12.7 years y 1 1.5 1 mm y pall., thal., dent. y
13.7 years y 1 1.5 1 mm y pall., thal., dent. y
15.7 years y 4 1.5 1 mm y pall., thal., dent. y
p2b high 15 years 14.7 years y mult. 3 2 mm y pall., dent. y
p3 high 22 years 22.4 years n - - 1 mm y dent. y
p4 high 29 years 29.4 years n - - 6 mm y dent. y
29.6 years n - - 6 mm y dent. y
38.3 years n - - 2 mm y dent. y
40.4 years n - - 1 mm y dent. y
p5 high 18 years 31.1 year y 2 3 1 mm y dent. y
p6 high 25 years 37.9 years y mult. 19 1.3 mm y y
p7 high 71 year 61.8 years y 2 10 5 mm y right caudate (postischemic) y
65.1 year y 2 10 5 mm y right caudate (postischemic) y
66.4 years y 3 12 4 mm y right caudate (postischemic) y
70.2 years y 4 13 4 mm y right caudate (postischemic) y
72.1 year y 4 13 4 mm y right caudate (postischemic) y
73.8 years y 5 13 1 mm y right caudate (postischemic) y
p8b high 66 years 66.3 years y 1 17 6 mm y y
Controls #
c1c high 8 d 6.2 years n - - 1 mm y y
c2c high 17 d 7.2 years n - - 1 mm n righ thal., dent. n
9.5 years n - - 1 mm n righ thal., dent. n
c3 low 10 week 8.7 years n - - 1 mm n n
c4 low 10 d 10.6 years n - - 1 mm n n
c5 low 13 m 11.0 year n - - 1 mm n n
c6c high prenatal 11.0 year n - - 3.6 mm y palllidum y
13 .0 year n - - 3.6 mm y palllidum y
15.1 year n - - 2 mm y palllidum y
19.1 year n - - 1 mm y palllidum y
c7 high 3 m 14.0 year y 1 2 3.6 mm y palllidum y
16.0 year y 2 2 3.6 mm y palllidum y
18.0 year y 2 3 2 mm y palllidum y
22.1 year y 2 3 1 mm y palllidum y
c8 low 36 m 16.0 year n - - 1 mm n n
d days, dent. dentate nucleus, m months, mul. multiple, n.d. not determined, NBS newborn screening, pall. pallidum, scr. screening, sib. sibling., thal. thalamus, yrs,
years. a initial findings including MRIs at 8.5, 9.5, 10.4 years were reported in Harting et al. 2009 as case 5; b reported in [12]; c initial findings of c1, c2, and c6 were
reported in Harting et al. 2009 (c1 = case 2 (≤50 months), c2 = case 3 (≤36 months), c6 = case 4 (≤15 years), [18])
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Grey matter changes
No patient had striatal changes typical of GA1. Unilat-
eral gliosis defect and susceptibility artefact of the right
anterior caudate and lenticular nucleus in p7 was con-
sistent with postischemic residuum. New cortico-
subcortical ischemic lesions as well as stenosis of the
left medial cerebral artery developed during follow-up
and stenosis of the left medial cerebral artery became
apparent on MRI at the age of 70 years, not different
from non-GA1 patients with arterial hypertension and
atherosclerosis.
Pallidal hyperintensity was observed in two late-onset
and two high-excreting control patients with additional
T2-hyperitensity of the dorsomedial thalamus in one
late-onset patient (p1; Fig. 2d). The dentate nucleus was
T2-hyperintense in five late-onset and one high-
excreting control patient. In one control patient (c2)
slight enlargement of the right dorsal thalamus with
focal T2-hyperintensity had been present since the age
of 7 months differing by its slight T1-hypointensity from
thalamic signal alterations in p1 (Fig. 1c).
Deep grey matter T2-hyperintensity remained un-
changed in the two late-onset (p1, p4) and the two con-
trol patients (c6, c7) with follow-up periods between 7
and 11 years.
Subependymal lesions
Subependymal lesions were observed in six late-onset
patients, namely all but the two maternal GA1 patients,
and in one high-excreting control patient (c7). All le-
sions were located at the border of the lateral ventricles,
most commonly the roof, ranging from single, (semi-
)nodular lesions to multiple lesion of up to 19 mm
diameter (Fig. 3). They were not observed before the age
of 12 years.
In the three younger late-onset patients diagnosed be-
tween eight and 18 years (p1, p2, p5) and in control pa-
tient c7 with MRIs at 14–22 years, subependymal lesions
Fig. 1 Normal frontotemporal anatomy and examples of
frontotemporal hypoplasia. a-c Normal Sylvian fissure and anterior
temporal CSF spaces in control patient c2. NB asymmetric thalamus
with focal T2-hyperintensity and facilitated diffusion (inset: ADC
map). d-i Mild hypoplasia in late-onset patient p1 not extending
dorsally beyond the pars opercularis (arrow in d) of the inferior
frontal gyrus and remaining unchanged between first MRI at
8.6 years (d-f) and last follow-up MRI at 15.7 years (g-i). NB T2-
hyperintensity of pontine white matter and dentate nucleus (H).
j-l Moderate hypoplasia involving the subcentral gyrus in late-onset
patient p6 (arrow in j). NB subependymal nodules and focal,
asymmetric white matter changes (l). m-r Widely open Sylvian
fissure and massively widened anterior temporal CSF spaces in
late-onset patient p7 unchanged between MRIs at 61 and 73 years.
NB large, subependymal, FLAIR-hyperintense nodule in right frontal
horn (o, r; also Fig. 3). (T1w: a, g, m, p; T1w + GAD: j; T2w: b, c, e, f,
h, i; FLAIR: K, l, n, o, q, r; ADC: inset in c)
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presented as small, smooth, round thickenings of the
ventricular border of up to 3 mm diameter with isoin-
tensity in T2- and T1-weighted images compared to nor-
mal white matter. Follow-up MRIs of p1, p7, and c6
suggest slow growth based on lack of significant change
of a 1.5 mm seminodular lesion during a three year
period in p1, a slight increase from 2 to 3 mm during
eight years in c6 and an increase from 10 to 13 mm dur-
ing 12 years in p7. In p1 four additional, presumably in-
cipient lesions were identified in the last MRI at the age
of 15.6 years: Circumscribed thickenings of the ventricu-
lar roof, contrasting with the T1-hypointense, T2-
hyperintense periventricular white matter changes
(Fig. 3a-f ). Similar, presumably incipient lesions were
also present in p5 as a single and in p2 as multiple,
punctate nodularities in the roof of the lateral ventricles
(Fig. 3g-l). In p7 four additional lesions were detected
during 12 years of follow-up including a punctate, pre-
sumably incipient lesion in the roof of the right lateral
ventricle at last follow-up (Fig. 3s-z).
In general, lesions in p6-8, who were diagnosed between
25 and 71 years and imaged between 38 and 70 years, were
larger with maximum diameters between 13 and 19 mm, a
lobulated contour, one to two punctate susceptibility arte-
facts, and facilitated diffusion on ADC maps. None had
decreased diffusion as an indicator of high cellularity.
Some large lesions were inhomogeneous with cystic areas
with elevated ADC and FLAIR-hypointensity. In addition
Fig. 2 Examples of white and grey matter changes. a Mild,
predominantly periventricular white matter changes (arrows) in
control patient c1. b Focal and confluent, slightly asymmetrical white
matter changes as well as mild periventricular white matter
hyperintensity (arrows) in late-onset patient p5. c, d Extensive white
matter changes in late-onset patient p1 at 8.5 (c) and 15.7 years (d)
with slight progression during follow-up (e.g. temporal, arrows d,
compare with c). NB T2-hyperintensity of pallidum and medial
thalamus is only depicted at follow-up (d, arrow to right thalamus)
due to different slice angulation of examinations. e, f Extensive white
matter changes in control patient c6 without progression between
11 (e) and 19 years (f) involving periventricular, lobar, and subcortical
white matter. Pattern of involvement is similar to p1 with a rim of
near normal signal (arrows) interspersed between changes of
periventricular and more peripheral white matter. g, h. White and
grey matter changes in late-onset patient p7 at the age of 61 (g) and
73 years (h). At the age of 61 years there is a combination of mild,
periventricular and multiple, brighter white matter hyperintensities
undistinguishable from hypertensive white matter changes observed
in non-GA1-patients at this age. Subacute ischemia of the right
dorsolateral medulla oblongata (arrows in g1,2), which was the cause
of the acute neurological presentation, retracts over time (arrow in
h1) as does the pre-existing anterior lenticular and caudate defect
(arrow in g4, compare with h4). By the age of 73 years, white matter
changes have increased. Bilateral occipital (arrows in h2,3, compare
with g3) and hemodynamic ischemia in the left parietal border zone
(arrows in g4,5) have left defects and gliosis and there is overall volume
loss with widening of ventricles and sulci. (T2w: a-f, g2, h1; FLAIR: g1,
g3–6, h2–6)
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to linear superficial enhancement consistent with veins in
p6 and p7, there was some punctate superficial enhance-
ment not clearly vascular in p6 with the largest lesions.
Discussion
We systematically analyzed neuroradiological changes,
clinical, and biochemical data in eight patients with late-
onset GA1. The main results of this study are that (1)
clinical presentation is non-specific, that all late-onset
patients were (2) high-excretors, have (3) characteristic
frontotemporal hypoplasia, and (4) commonly subepen-
dymal lesions seen on cerebral MRI.
Clinical characteristics of late-onset patients
Late-onset GA1 was first reported in a 19 year old pa-
tient with headache, nystagmus, upward gaze palsy, fine
motor disturbances, and leukoencephalopathy [10]. Add-
itional patients diagnosed between the age of eight and
66 years were subsequently published [9–16, 22–27], in-
cluding two patients [12] and the initial case of p1 [18]
previously reported by our group, who are included in
this study, and four patients with maternal GA1 [14–
16]. Noteworthy, four of these patients had striatal
changes on MRI and/or symptoms of a complex dys-
tonic movement disorder thus qualifying them as insidi-
ous-onset type [10, 25–27]. One patient diagnosed by
genetic family counselling was asymptomatic [23]. In
three reported patients macrocephaly and developmental
delay/learning disability without motor symptoms had
already been noticed during infancy and childhood [11,
15] suggesting late diagnosis rather than late onset in
some patients. As in patients with acute and insidious
Fig. 3 Examples of subependymal lesions. a-f MRI of late-onset patient p1 at the age of 15.7 years with the (pre-existing) nodular subependymal
lesion in the medial roof of the right lateral ventricle (arrows in a, d, f3) and four incipient lesions in the roof of both lateral ventricles (arrows in a
(lat.), b and f2, in c and f3,5, in e and f1). (a: T2w; b-f: T1w). g-l MRI of late-onset patient p2 at 14.7 years with multiple, small, FLAIR-hyperintense
nodularities (g, h, arrows) resulting in a “bumpy” surface of the ventricular roof on the T2w sagittal images (i right, k left lateral ventricle) and one
larger nodule in the roof of the left ventricle without enhancement (arrows in j, l1, l2). NB extensive white matter changes. (g, h: FLAIR; i-k: T2w; l1,
l,2: T1w ± GAD). m-r Late-onset patient p6 with the most extensive, confluent subependymal lesions with multiple, small cystic areas (hypointense
on FLAIR-images m, n, arrows in n), facilitated diffusion (r), punctate susceptibility artefacts (arrows in q) and punctate enhancement (compare p
with o). (m, n: FLAIR; o, p: T1w ± GAD, q: T2*; r: ADC). s-z MRIs of late-onset patient p7 at the age of 61 (S-U) and 73 years (v-z). Initially there are
two lesions, a small one in the left anterior horn (arrow in s) without significant change on follow-up (arrows in v, z2) and a larger one in the right
anterior horn (s, z2, arrows in t, u), which increases mildly in size from approx. 10x9x8 mm to 13x9x9 mm during the 12 year period. Punctate
susceptibility artefacts (arrows in w), facilitated diffusion (x), and some superficial, linear enhancement (compare y1 with y 2 and z1 with z 2) are
present, similar to the large lesions in p6. Two additional, small nodules in septal surface of the right anterior and the roof of the left horn (arrows
in z 3,4) have been detectable and without significant changes since MRIs at 65 and 66 years. MRI at 73 years depicts an additional, incipient
lesion in the roof of the right lateral ventricle (arrow in z5). (s, v: FLAIR; t: T2w; u, y1, z2–5: T1w, y2,, z1: T1w + GAD, w: SWI; x: ADC)
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onset, macrocephaly was not a reliable clinical indicator,
being present in only 50% of our late-onset patients. In one
patient, it remained an isolated clinical finding until the
onset of headaches at age 35 years, subsequently followed
by tremor and seizures and later dementia (p8, [12]).
Similar to previous reports, clinical manifestation in
our patients was non-specific and more severe in older
compared to younger patients: While our oldest patients
in and above the 7th decade had clear neurologic signs
and symptoms, younger patients were either asymptom-
atic females identified via their children or predomin-
antly presented with headache, vertigo and nausea.
These are common, non-specific, but not necessarily
neurologic symptoms which in our experience are some-
times described by GA1 patients after excessive protein
intake.
Effects of age at diagnosis on clinical manifestation are
difficult to determine since our control patients were no
older than 22 years at last follow-up. Three of the six
late-onset patients diagnosed before the age of 30 years
had (non-specific) symptoms compared to only one of
eight control patients, which suggests a higher probabil-
ity of symptoms in late-onset patients. This observation
is limited by the small number of patients and may re-
sult from early treatment of control patients compared
to late-onset patients.
MRI in late-onset patients
1. Frontotemporal hypoplasia
Enlarged anterior temporal CSF spaces, incomplete
opercularization, and widening of the Sylvian Fissure
are the most common and characteristic imaging
finding in GA1. They are already present at birth in
preterm and term babies and can even be observed
during the last trimester of pregnancy [18, 28–30].
The appearance of the anterior temporal lobe and
Sylvian fissure in infants is similar to stages of
normal development, gyration and opercularization
occurring latest in the fronttemporal area. Moreover
CSF spaces have been observed to normalize in GA1
patients with early diagnosis and treatment [18, 19,
31–33], for which reason widened anterior temporal
and Sylvian CSF spaces in GA1 are consistent with
arrested development of the anterior temporal and
frontal lobes, namely frontotemporal hypoplasia, but
not with atrophy, as there is primarily no irreversible
loss of tissue.
Similar to patients diagnosed in infancy and
childhood, frontotemporal hypoplasia is the most
common and characteristic imaging finding in
late-onset patients. Frontotemporal hypoplasia
persisted in our three late-onset patients over
follow-up periods between 7 and 12 years suggesting
that normalization is only possible up to a certain
period of time.
2. White matter changes
White matter changes were the most striking
imaging finding in the first patient reported as
late-onset and have been reported for all late-onset
patients [9–13, 22–27]. They are also frequent in
patients with acute or insidious-onset type,
apparently increasing with age [18]. Consistent with
the literature, they were present in all our late-onset
patients but - being non-specific - they are not
decisive for the diagnosis of late-onset patients.
Though more frequent in late-onset compared to
control patients they do not allow differentiation
from either early diagnosed and treated control
patients or from patients with acute or insidious-
onset type.
3. Subependymal lesions
Subependymal mass lesions have been reported in
three late-onset patients aged 30 to 56 years [13, 22,
23]. In our cohort, subependymal lesions were
detected in six of eight late-onset patients - all but
the two maternal GA1 patients - and in one control
patient (c7). In spite of our small study group this
high frequency suggests that subependymal lesions
are common in late-onset GA1 and that they may
also occur in adolescent patients treated since
childhood. Lesion growth as seen in our three late-
onset patients with follow-up MRIs appears to be
slow. Lesion number and size apparently increase
with age and might moreover be related to age at
diagnosis.
Similar to reported patients, location of lesions was
exclusive to the lateral ventricles with a predilection
for the roof. Location, slow growth, and signal
would be consistent with subependymoma. Though
somewhat reminiscent of the subependymal
hamartomas and subependymal giant astrocytomas
of tuberous sclerosis, subependymal lesions of GA1
lack the predilection for the caudothalamic groove.
As yet, histopathology has not been reported. With
regard to pathogenesis subependymal lesions might
reflect distribution of the neurotoxic metabolites GA
and 3-OH-GA and/or brain susceptibility, as GA
and 3-OH-GA accumulate within the brain due to
restricted flux across the blood–brain barrier [34, 35].
Late-onset GA1 - a variant with solely chronic
neurotoxicity in patients with a high-excreting phenotype
During the last years, the terms insidious and late-onset
have been used for patients whose clinical manifestation
differs from acute-onset type GA1. Patients with insidi-
ous-onset develop a complex dystonic movement dis-
order due to striatal injury but without clinically
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apparent precipitating event, hereby differing from pa-
tients with acute-onset [36], while the term late-onset
has been proposed for patients presenting after the age
of six years. It is currently not clear whether or not late-
onset patients represent a distinctive disease variant, in
particular since some reported patients had striatal
changes on MRI and/or signs of a dystonic movement
disorder thus fulfilling the criteria for insidious-onset
type GA1 [10, 25–27]. We therefore only included pa-
tients without either clinical or MRI evidence of striatal
lesions in our study, namely those patients who - though
untreated - did not suffer striatal injury despite various
infections and other potential triggers during infancy
and childhood.
Absence of clinical or MR evidence of striatal injury is
a feature shared by both, our late-onset and early treated
control patients. However, while both groups are ex-
posed to chronic neurotoxicity, cumulative neurotoxicity
should be less in control patients due to early start of
metabolic treatment, since metabolic treatment is aimed
at reducing the intracerebral accumulation of the neuro-
toxic metabolites GA and 3-OH-GA. Proof of concept
has been demonstrated in Gcdh−/− mice [37]. Conse-
quently, greater cumulative neurotoxicity might explain
the (non-specific) symptoms in three of the six late-onset
patients diagnosed between the age of 8.5 and 29 years
compared to one of eight control patients with last fol-
low up between the ages of 9 and 26 years.
Treatment however does not preclude development or
progression of MR changes in late-onset or control pa-
tients, e.g. white matter changes were slightly progres-
sive in late-onset patient p1 despite initiation of
treatment and resolution of clinical symptoms and de-
veloped in control patient c5 between MRIs at 4 and
11 years (for initial findings which have been previously
been reported by us see case 4 in [18]). Another example
is the detection of subependymal nodules in late-onset
patient p1 and control patient c7 after initiation of
treatment.
The exclusively high excreting phenotype of late-on-
set patients in our study was unexpected, since the pro-
portion is approximately two thirds in infants and
children with GA1 [2, 38]. A correlation of genotype
with biochemical phenotype has been reported in GA1,
whereas as yet no correlation of either genotype or bio-
chemical phenotype with clinical phenotype is known
[2, 38, 39]. High excretors show a complete loss of
GCDH activity in contrast to up to 30% residual en-
zyme capacity in low excretors who predominantly
carry missense mutations on at least one GCDH allele
[5, 39]. Without treatment high- and low-excretors
have a similar risk of developing striatal damage and
dystonia which determine clinical outcome [2]. This
has been explained by entrapment of neurotoxic
metabolites in the brain compartment and, subse-
quently, high cerebral concentrations of GA and 3-OH-
GA in both, low- and high-excreting patients [34, 35].
However, several observations challenge this view and in-
dicate an increasing influence of the biochemical phenotype
with growing age: All our late-onset patients are high excre-
tors and no low-excreting late-onset patient has been
reported. In addition, MRI was normal in all four low-
excreting control patients, but in none of the high-
excreting control patients. This finding, however, is limited
by the small number of control patients. In addition, we
have recently unravelled the high excreting phenotype to be
a risk factor for increased chronic cerebral GA accumula-
tion and progressive neuroaxonal compromise in high-
excretors compared to low excretors [40]. We therefore
hypothesize that the biochemical phenotype co-determines
whether or not clinical signs and symptoms will occur in
potential late-onset patients and that this is related to
higher degree of chronic neurotoxicity with greater intrace-
rebral accumulation of GA and 3-OH-GA in high excre-
tors. Further studies are necessary to evaluate differences in
the clinical course in both biochemical subgroups and to
elucidate the impact of MR changes on clinical phenotype.
Conclusion
While clinical manifestation is non-specific in late-onset
GA1, frontotemporal hypoplasia in particular if in com-
bination with subependymal nodules is characteristic of
late-onset GA1 and should trigger investigation for GA1.
Apart from their apparent non-susceptibility for stri-
atal injury despite lack of treatment, patients with late-
onset GA1 are not categorically different from early
treated control patients. We hypothesize that “late-onset
GA1” is the result of long-term toxicity in untreated
GA1 patients with a high excreting phenotype. Accord-
ingly, differences between “late onset GA1” and early
treated patients might reflect the higher long-term risk
of high excretors compared to low excretors and of indi-
viduals remaining undiagnosed and untreated for years,
even decades. As long-term clinical outcome in GA1 is
unclear, implementation of this observation for clinical
management and monitoring remains to be elucidated.
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